These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18854445)

  • 1. CT and MR imaging of progressive dural involvement by nephrogenic systemic fibrosis.
    Zelasko S; Hollingshead M; Castillo M; Bouldin TW
    AJNR Am J Neuroradiol; 2008 Nov; 29(10):1880-2. PubMed ID: 18854445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.
    Bernstein EJ; Schmidt-Lauber C; Kay J
    Best Pract Res Clin Rheumatol; 2012 Aug; 26(4):489-503. PubMed ID: 23040363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrogenic systemic fibrosis in the podiatric patient.
    Freed L; Hill J; Gooch D
    J Am Podiatr Med Assoc; 2012; 102(5):419-21. PubMed ID: 23001737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythema nodosum masking nephrogenic systemic fibrosis as initial skin manifestation.
    Fuah KW; Lim CTS
    BMC Nephrol; 2017 Jul; 18(1):249. PubMed ID: 28738858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of NSF-active and NSF-inert in nephrogenic systemic fibrosis.
    Wiginton CD
    AJR Am J Roentgenol; 2008 Dec; 191(6):1864-6. PubMed ID: 19020261
    [No Abstract]   [Full Text] [Related]  

  • 6. Contemporary applications and limitations of magnetic resonance imaging contrast materials.
    Natalin RA; Prince MR; Grossman ME; Silvers D; Landman J
    J Urol; 2010 Jan; 183(1):27-33. PubMed ID: 19913804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nephrogenic fibrosing dermatosis: From clinic to microscopy].
    Yoldez H; Ahlem B; Abderrahim E; Faten Z; Soumaya R
    Nephrol Ther; 2018 Feb; 14(1):47-49. PubMed ID: 29239786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
    Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
    Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrogenic systemic fibrosis.
    Kaewlai R; Abujudeh H
    AJR Am J Roentgenol; 2012 Jul; 199(1):W17-23. PubMed ID: 22733927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
    Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE
    Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A; Witzke O; Hillen U; Barkhausen J; Daul AE; Erbel R
    J Am Coll Cardiol; 2009 May; 53(18):1621-8. PubMed ID: 19406336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review.
    Sanyal S; Marckmann P; Scherer S; Abraham JL
    Nephrol Dial Transplant; 2011 Nov; 26(11):3616-26. PubMed ID: 21441397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.
    Larson KN; Gagnon AL; Darling MD; Patterson JW; Cropley TG
    JAMA Dermatol; 2015 Oct; 151(10):1117-20. PubMed ID: 26017458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk.
    Nicholas BA; Vricella GJ; Smith M; Passalacqua M; Gulani V; Ponsky LE
    Can J Urol; 2012 Feb; 19(1):6074-80. PubMed ID: 22316507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior vena cava obstruction associated with nephrogenic systemic fibrosis.
    Holzem KE; Nardone B; Lomasney JW; Yazdan P; Gerami P; West DP; Laumann AE
    J Drugs Dermatol; 2014 May; 13(5):615-8. PubMed ID: 24809889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular pathologic features and gadolinium deposition in nephrogenic systemic fibrosis.
    Barker-Griffith A; Goldberg J; Abraham JL
    Arch Ophthalmol; 2011 May; 129(5):661-3. PubMed ID: 21555622
    [No Abstract]   [Full Text] [Related]  

  • 17. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis.
    Bertero M; Bainotti S; Comino A; Formica M; Giordano F; Musso L; Palazzini S; Seia Z
    Eur J Dermatol; 2009; 19(1):73-4. PubMed ID: 19171533
    [No Abstract]   [Full Text] [Related]  

  • 18. Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era.
    Thomson LK; Thomson PC; Kingsmore DB; Blessing K; Daly CD; Cowper SE; Roditi GH
    J Magn Reson Imaging; 2015 May; 41(5):1268-71. PubMed ID: 24903851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NSF-active and NSF-inert species of gadolinium: mechanistic and clinical implications.
    Kuo PH
    AJR Am J Roentgenol; 2008 Dec; 191(6):1861-3. PubMed ID: 19020260
    [No Abstract]   [Full Text] [Related]  

  • 20. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.